GET DAILY SIGNALSJohnson & Johnson (JNJ) Posts Solid Q2 Results With +6.6% Sales Growth and Raised Full-Year Guidance
Key Takeaways
- Johnson & Johnson reported second-quarter 2026 sales of $25.3 billion, up 6.6% year over year on a reported basis.
- Adjusted earnings per share reached $2.90, exceeding the consensus estimate of $2.85.
- Reported earnings per share came in at $2.27 for the quarter.
- The company raised its full-year 2026 guidance for both sales and adjusted earnings per share.
- Operational sales growth stood at 5.6%, with adjusted operational growth at 5.7%.
- Results position the company to surpass $100 billion in annual revenue for the first time.
Why These Results Matter
Johnson & Johnson’s second-quarter update offers a useful snapshot of momentum in its innovative medicine and medtech businesses. These quarterly reports matter because the company’s broad portfolio and development pipeline shape expectations for long-term revenue and cash generation. Consistent execution on product launches and pricing often shows up in these numbers, especially in a competitive healthcare sector. With the firm now on track to exceed $100 billion in annual sales for the first time, the latest figures help gauge progress and inform views on capital allocation going forward.
The Quarter in Detail
Johnson & Johnson delivered second-quarter 2026 sales of $25.3 billion, reflecting 6.6% reported growth, 5.6% operational growth, and 5.7% adjusted operational growth versus the prior year. Reported earnings per share totaled $2.27, while adjusted earnings per share reached $2.90, beating the analyst consensus of $2.85. The company raised its full-year 2026 outlook, now projecting reported sales of $101.1 billion at the midpoint (7.3% growth) and lifting adjusted earnings per share guidance by $0.13 to $11.68 at the midpoint. These figures underscore strength in key therapeutic areas and operational discipline, with quarterly sales crossing the $25 billion mark for the first time.
When reviewing industry comparisons, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction
Shares of Johnson & Johnson saw modest pressure after the release even though the earnings beat came through, as some investors focused on softer medtech performance. Overall sentiment stayed constructive given the raised full-year guidance and continued progress toward the $100 billion revenue target. Analysts viewed the adjusted earnings beat and upward outlook revision as positive, while noting the importance of sustained execution in medtech to maintain momentum.
Looking Ahead
With the updated guidance in place, attention will turn to the pace of growth in innovative medicine, especially contributions from key products in oncology and immunology. Medtech results remain a key area to watch, since any improvement or further softness could affect overall margins and the revenue mix.
Supply chain stability, pricing trends, and regulatory developments for pipeline assets will also require monitoring in coming quarters. The company’s ability to turn pipeline progress into commercial results will influence the path toward its long-term revenue goal.
Broader industry dynamics, such as healthcare spending patterns and competitive pressures, could shape demand across segments. Cost control and margin expansion efforts will stay relevant alongside any updates on capital deployment plans.
Tools I Use for Deeper Analysis
In my own workflow, I often rely on Tickeron’s AI Screener to quickly filter stocks and ETFs by technical patterns, fundamentals, trends, volatility, and AI-driven signals. The platform lets users scan thousands of securities with customizable filters for industry, market cap, technical indicators, price patterns, and performance metrics, which helps surface ideas and compare opportunities more efficiently than manual reviews. AI Screener
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
JNJ's RSI Indicator climbs out of oversold territory
The RSI Indicator for JNJ moved out of oversold territory on October 07, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 18 of the 30 cases the stock moved higher. This puts the odds of a move higher at 60%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 33 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 39%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 19 of 47 cases over the following month. The odds of a continued upward trend are 40%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 41%.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 163 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 28 of 62 cases where JNJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 45%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 21 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.673) is normal, around the industry mean (-1.619). P/E Ratio (30.992) is within average values for comparable stocks, (21.766). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.020) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement